Skip to main content

Simon Barry J.'s Form 4 filing

ImmunityBio, Inc. (IBRX) · filed Jun 5, 2026

Accession no.
0001647994-26-000008
Filed
Jun 5, 2026
Trade date
Jun 4, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 1 non-derivative transaction. Open-market sales total $165.4K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Simon Barry J.CIK 0001647994Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 4, 2026Common StockSSaleDisposed−23,033$7.18F2−$165,376.942,827,788Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average share price of an aggregate total of 23,033 shares sold in the price range of $7.125 to $7.225 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)